139 related articles for article (PubMed ID: 23826550)
1. Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature.
Firwana B; Atassi B; Hasan R; Hasan N; Sukari A
Avicenna J Med; 2012 Jul; 2(3):71-73. PubMed ID: 23826550
[TBL] [Abstract][Full Text] [Related]
2. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study.
Dori S; Vered M; David R; Buchner A
J Oral Pathol Med; 2002 Sep; 31(8):463-7. PubMed ID: 12220353
[TBL] [Abstract][Full Text] [Related]
3. Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab.
Ghazali N; Parker L; Settle K; Lubek JE
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):292-9. PubMed ID: 27289263
[TBL] [Abstract][Full Text] [Related]
4. [The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands].
Golusiński W; Wegner A; Trzeciak P; Golusiński P; Sówka M; Kopczyński A; Bromboszcz M; Marszałek A
Otolaryngol Pol; 2013; 67(5):245-51. PubMed ID: 24021827
[TBL] [Abstract][Full Text] [Related]
5. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
[TBL] [Abstract][Full Text] [Related]
6. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
[TBL] [Abstract][Full Text] [Related]
7. Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.
Skálová A; Stárek ; Kucerová V; Szépe P; Plank L
Pathol Res Pract; 2001; 197(9):621-6. PubMed ID: 11569926
[TBL] [Abstract][Full Text] [Related]
8. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
Sharon E; Kelly RJ; Szabo E
Head Neck Oncol; 2010 May; 2():12. PubMed ID: 20504363
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab for the treatment of salivary duct carcinoma.
Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI
Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737
[TBL] [Abstract][Full Text] [Related]
10. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.
Haddad R; Colevas AD; Krane JF; Cooper D; Glisson B; Amrein PC; Weeks L; Costello R; Posner M
Oral Oncol; 2003 Oct; 39(7):724-7. PubMed ID: 12907212
[TBL] [Abstract][Full Text] [Related]
11. Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature.
Krishnamurthy J; Krishnamurty DM; Baker JJ; Zhen W; Lydiatt D; Ganti AK
Head Neck; 2013 Dec; 35(12):E372-5. PubMed ID: 23765450
[TBL] [Abstract][Full Text] [Related]
12. HER2 expression in salivary gland carcinomas: dependence on histological subtype.
Glisson B; Colevas AD; Haddad R; Krane J; El-Naggar A; Kies M; Costello R; Summey C; Arquette M; Langer C; Amrein PC; Posner M
Clin Cancer Res; 2004 Feb; 10(3):944-6. PubMed ID: 14871971
[TBL] [Abstract][Full Text] [Related]
13. Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy.
Ueki Y; Tada Y; Togashi T; Kawakita D; Nagao T; Sato Y
Int Cancer Conf J; 2016 Jul; 5(3):150-153. PubMed ID: 31149444
[TBL] [Abstract][Full Text] [Related]
14. Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature.
Alotaibi AM; Alqarni MA; Alnobi A; Tarakji B
J Clin Diagn Res; 2015 Feb; 9(2):ZE04-8. PubMed ID: 25859537
[TBL] [Abstract][Full Text] [Related]
15. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
[TBL] [Abstract][Full Text] [Related]
17. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.
De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM
Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571
[TBL] [Abstract][Full Text] [Related]
18. Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature.
Goodman OB; Milowsky MI; Kaplan J; Hussain M; Nanus DM
J Med Case Rep; 2009 Sep; 3():9110. PubMed ID: 19918289
[TBL] [Abstract][Full Text] [Related]
19. ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas: Clinicopathologic and Molecular Analysis of 4 Cases and Literature Review.
Agaimy A; Baněčková M; Ihrler S; Mueller SK; Franchi A; Hartmann A; Stoehr R; Skálová A
Am J Surg Pathol; 2021 Sep; 45(9):1166-1178. PubMed ID: 33871952
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Falchook GS; Lippman SM; Bastida CC; Kurzrock R
Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
